Three Metabolic Research Peptides, One Framework

The short version

Freebase Peptides is a reading desk, not a store. It collects what the published research literature actually says about three peptides studied for metabolic regulation and weight management: retatrutide, MOTS-c, and tesamorelin. A peptide is a short chain of amino acids — the same building blocks proteins are made of, but far smaller and more targeted. Each of these three has been studied because it engages a distinct part of the body's metabolic machinery: retatrutide simultaneously activates three hormone receptors that control appetite, energy expenditure and glucose; MOTS-c is a mitochondria-encoded signal that activates AMPK, the body's cellular fuel gauge; tesamorelin stimulates the pituitary to release growth hormone, selectively mobilizing visceral fat.

This desk does one job: it tells you, in plain language and with citations, what each peptide was tested on, in which species, and how far that evidence really reaches. The approval statuses differ meaningfully. None of these is a general-purpose treatment, and none is presented here with a human dose or a medical recommendation.

What are research peptides?

Proteins in your body — a hormone, an enzyme, a structural fiber — are long chains of amino acids folded into a precise shape. A peptide is a much shorter chain of the same amino acids, sometimes only a dozen links long. Because they are small and specific, peptides can bind particular receptors on cell surfaces, switching targeted processes on or off.

A research peptide is one that has been synthesized and studied in laboratories — in cell cultures, in animals, and in some cases in early human trials — but has not necessarily been approved by a regulator as a medicine for any given use. One compound on this desk (tesamorelin) is FDA-approved for a specific and limited indication; the other two are in different stages of research. When this site reports a number — a percentage weight reduction, a change in visceral fat — it reports it exactly as the study did, in the population and route studied. Never as a recommendation.

How these three fit into metabolic research

The three peptides on this desk attack metabolism from different angles, which is why they belong together.

• Retatrutide is the lead. It is an investigational 39-amino-acid peptide that agonizes the GIP, GLP-1, and glucagon receptors on a single molecule. Phase 2 trials showed a mean weight reduction of approximately 24% over 48 weeks in adults with obesity — the largest signal in the incretin class to date ^[4]. Phase 3 trials are ongoing as of mid-2026; it is not approved by any regulator.
• MOTS-c is encoded not in the nuclear genome but in the mitochondrial genome — an unusual origin for a peptide hormone. Its primary metabolic action is inhibiting the folate cycle, which raises AICAR and activates AMPK in skeletal muscle, improving glucose handling and insulin sensitivity ^[10]. Animal studies show it enhances physical performance, and it is described as an exercise-mimetic regulator of aging ^[11]. No human efficacy trials exist.
• Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, amplifying the body's own pulsatile growth-hormone rhythm. The resulting GH/IGF-1 signal preferentially mobilizes visceral fat. It is FDA-approved for a specific HIV-associated lipodystrophy indication; a 2026 meta-analysis confirmed it reduces visceral adipose tissue by a mean of 27.71 cm² across five RCTs ^[13].

Together they sketch the metabolic problem from several directions: receptor-driven appetite and energy regulation, mitochondrial fuel-sensing, and pituitary-axis modulation. Use the directory to read each one, or compare these peptides side by side.

A note on how this desk reads the literature

Freebase Peptides is a cross-referenced literature digest. Each peptide page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a single shared references list that aggregates every source. Where the evidence is thin, preclinical, or limited to a specific population, we say so plainly — that framing is part of the record, not a footnote. We describe research findings and cited cautions; we do not recommend, prescribe, or sell. The aim is an accurate clinical briefing on what is known, so you can see where the evidence is solid and where it remains preliminary.